Ocuphire Pharma Investor Day Presentation Deck slide image

Ocuphire Pharma Investor Day Presentation Deck

P Key Findings from GlobalData Market Research on Presbyopia Insights Very Consistent with Other Competitors Market Research Surveys 120+ Million Presbyopia patients in the US 51% physicians would offer eye drops as a first-line presbyopia treatment 102 90% presbyopia patients wear reading glasses ≥ once per day Physician Perspective N=120 Global Data Market Research Survey 67% physicians indicated interest in Nyxol+LDP 70% patients would consider an eye drop as an alternative to reading glasses 70% patients considered the 2 drops/bottle dosing to be moderately-to-very convenient 40% patients have asked their physicians about alternatives to reading glasses ≥ $50/mo Patient Willing to Pay Vuity ™M is priced at $79 for a 30-day supply Patient Perspective n-=134 Ocuphire PHARMA
View entire presentation